Copyright
©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Aug 9, 2018; 8(4): 84-96
Published online Aug 9, 2018. doi: 10.5500/wjt.v8.i4.84
Published online Aug 9, 2018. doi: 10.5500/wjt.v8.i4.84
Hepatitis C and renal transplantation in era of new antiviral agents
Maurizio Salvadori, Department of Transplantation Renal Unit, Careggi University Hospital, Florence 50139, Italy
Aris Tsalouchos, Nephrology and Dialysis Unit, Saints Cosmas and Damian Hospital, Pescia 51017, Italy
Author contributions: Salvadori M and Tsalouchos A contributed equally to the manuscript; Salvadori M designed the study, performed the last revision and provided answers to the reviewers; Tsalouchos A collected the data from literature; Salvadori M and Tsalouchos A analyzed the collected data and wrote the manuscript.
Conflict-of-interest statement: Maurizio Salvadori and Aris Tsalouchos do not have any conflict of interest in relation to the manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Maurizio Salvadori, MD, Professor, Department of Transplantation Renal Unit, Careggi University Hospital, viale Pieraccini 18, Florence 50139, Italy. maurizio.salvadori1@gmail.com
Telephone: +39-55-597151 Fax: +39-55-597151
Received: February 28, 2018
Peer-review started: March 1, 2018
First decision: March 29, 2018
Revised: April 17, 2018
Accepted: May 30, 2018
Article in press: May 30, 2018
Published online: August 9, 2018
Peer-review started: March 1, 2018
First decision: March 29, 2018
Revised: April 17, 2018
Accepted: May 30, 2018
Article in press: May 30, 2018
Published online: August 9, 2018
Core Tip
Core tip: The prevalence of hepatitis C virus (HCV) infection is high in patients with end-stage renal disease and HCV has clinical challenges in patients who undergo kidney transplantation. Historically, interferon-based treatment options have been limited by low rates of efficacy and significant side effects, including risk of precipitating rejection. Direct acting antiviral (DAA) drugs revolutionized the treatment of HCV. In this review we highlighted the most recent studies and clinical trial with DAA in renal patients including patients waiting for transplantation and already transplanted. In these studies all-oral DAA therapy appears to be safe and effective for such patients.